Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. erythroag

ERYTHROAG

A new ICT-based device (RHEO-01) for fast point-of-care analysis of acute ischemic stroke and other emergency situations.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 ERYTHROAG project word cloud

Explore the words cloud of the ERYTHROAG project. It provides you a very rough idea of what is the project "ERYTHROAG" about.

professionals    forecast    market    erythroag    rapid    aggregation    contextualized    starting    therapy    blood    disability    point    device    kinetics    profiles    dataset    percentage    input    rheo    5b    life    ict    varies    inflammation    rheofast    acute    trigger    patient    enrichment    update    care    440k    ischemic    people    decisions    proprietary    freedom    turn    forecasts    turnover    helping    30s    thrombolytic    remote    assist    erythrocyte    physician    translates    measured    decrease    data    burden    triggers    takes    middle    hemorrhagic    receiving    situation    frequent    physicians    risk    01    optically    minutes    patients    tool    saving    elderly    solution    ea    huge    operate    french    collection    poc    2018    emergency    clinical    gt    france    mathematical    efficient    imposes    differentiate    treatment    managed    standard    decision    quality    inflammatory    initially    displayed    economic    connected    alters    13    stroke    output    profile    health    smart    aged    mainly    1   

Project "ERYTHROAG" data sheet

The following table provides information about the project.

Coordinator		 RHEOFAST 

Organization address
address: 5 RUE HENRI DESBRUERES, GENOPOLE CAMPUS 1
city: EVRY
postcode: 91030
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country France [FR]
 Project website http://rheofast.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.4. (Active ageing and self-management of health)
2. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.3.1.6. (Health care provision and integrated care)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-08-01   to  2017-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RHEOFAST FR (EVRY) coordinator 50˙000.00

Map

 Project objective

Stroke is the most frequent cause of long-term disability in Europe, mainly in middle-aged and elderly people. Stroke imposes a huge health care economic burden: >5B€/year in France. RHEOFAST is developing a smart ICT-based decision support tool to assist health professionals in the efficient management of patients with acute stroke. RHEO-01 information management includes three aspects: 1- High quality data input from a connected point-of-care device that measure a patient’s inflammatory profile in 30s. The optically measured erythrocyte aggregation kinetics (EA) varies with inflammation. This information is contextualized by the patient’s clinical characteristics provided by physicians. 2-Remote smart data is managed with EA kinetics mathematical modelling, comparison with proprietary dataset and dataset enrichment with high quality data, 3- Physician-friendly output is displayed on the POC device to help physicians make treatment decisions. The whole process from standard blood collection to results takes less than 5 minutes. Acute ischemic stroke triggers inflammation, which in turn alters EA kinetics. Hemorrhagic stroke doesn’t initially trigger inflammation. By helping physicians to quickly differentiate patients with acute ischemic stroke from patients with hemorrhagic stroke, RHEO-01 will improve the percentage of patients receiving timely life-saving thrombolytic therapy. A 1% increase in thrombolytic treatment translates to a 440K€ decrease in cost (France). Furthermore, RHEO-01 can quickly identify inflammatory profiles in patients with other emergency conditions. Based on the French situation RHEOFAST forecasts a rapid growing turnover starting in 2018 with up to 13 M€ after 5 years. We need to have a European approach to update our forecast and propose our solution to health professionals all across Europe. This is the objective of the ERYTHROAG project, which includes technical risk analysis, market research and freedom to operate study.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ERYTHROAG" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ERYTHROAG" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.4.;H2020-EU.2.1.1.;H2020-EU.2.3.1.;H2020-EU.3.1.6.)

CLINICOVERY (2018)

CLINICOVERY, a versatile, high quality, environmental-friendly, easy to use e-Clinical solution for clinical research

Read More  

ClearRing (2018)

An innovative, minimally invasive medical device used for treatment of Benign Prostatic Hyperplasia symptoms.

Read More  

JUMPAIR (2018)

Decubitus Ulcers Diseases Diagnoses by means of Smart ICT Anti-Decubitus System based on known Ulcers Activity Biomarkers

Read More